If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
882.00    22.00 (2.56%)
Bid:
870.00
Ask:
892.00
Spread: 22.00 (2.529%)
Market Cap: £241.41m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Full Year Trading Update

7 Oct 2025 07:00

RNS Number : 2811C
Gooch & Housego PLC
07 October 2025
 

 

 

7 October 2025

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Full Year Trading Update

and

Notice of Results

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components and systems, announces its trading update for the financial year ended 30 September 2025.

 

Trading Update

 

Following the positive performance in the first half, the Group is pleased to report that trading momentum was sustained during the second half of the financial year ended 30 September 2025, despite continuing challenges from the global macroeconomic environment.

 

Industrial revenues for fibre optic couplers and modules used in subsea data networks grew, offsetting the broadly flat sales from our industrial laser customers. Whilst there are early signs of a recovery in demand from the semiconductor market, we continue to closely monitor the short-term uncertainty in our industrial markets created by ongoing macroeconomic and geopolitical challenges. Encouragingly, the medium-term underlying demand drivers remain positive for our industrial products, and customer activity increased towards the end of the financial year. We are well positioned to benefit from the recovery in these markets.

 

Life Sciences revenues in the second half of the financial year benefited from customer phasing of several medical diagnostic device programmes that are manufactured in Ashford, Kent. We have seen a positive response to the 'last time buy' notice for our Pockels Cells going into medical lasers, which will be delivered over the coming financial year, at which point our Cleveland, Ohio, facility will transition to further develop its capacity for the growth of crystals used both within our Group and by external customers for optical applications.

 

Aerospace & Defence saw further revenue growth in the second half underpinned by strong demand for our precision optics and advanced sighting and imaging systems in military platforms. Demand for our ring laser gyro components in the commercial aerospace sector also remains strong and we continue to benefit from operational improvements, together with additional capacity that we have added over the last couple of years.

 

Due to the positive trading performance in the year, enhanced by focused operational improvements, proactive handling of supply chain disruptions, investment to further enhance capability and the capitalisation of overheads in inventory, the Board expects to announce full year revenues and adjusted profit before tax broadly in line with its expectations, before moderately higher non-underlying costs of recent acquisitions and restructuring activities.

 

Integration of Acquisitions

 

The integration of Phoenix Optical and Global Photonics into G&H, both of which were acquired during the year, is proceeding to plan. The exploitation of operational and commercial synergies between Phoenix and the rest of the Group is already well underway with the main focus on germanium fabrication, and a number of newly combined optical substrate and coating offerings are now available to customers.

 

Global Photonics brings expertise in cleanroom lithography, photolithographic reticle fabrication, ion beam etching and advanced thin film coatings that is hugely complementary to G&H's existing manufacturing capabilities. This, along with the significant available space at the new Tampa facility, will help scale the Group's offering into North America to meet the growing demand from US defence prime contractors, particularly for laser protection filtering, periscopes and complex optical systems.

 

Both transactions represent 'speed to value' acquisitions for G&H focused on addressing the growing opportunities in the Aerospace & Defence sector and have been well received by customers with a number of exciting new potential orders being pursued.

Cash/Debt

The Group remains in a strong financial position with a robust balance sheet. Net bank debt excluding IFRS 16 at 30 September 2025 was £30.0m (31 March 2025: £24.1m; 30 September 2024: £16.0m), reflecting good operational cashflow before non-underlying items, investment in inventory and the acquisitions of Phoenix Optical and Global Photonics.

 

 

Outlook

 

The Group's order book continues to grow and at 30 September 2025 was £142.3m (31 March 2025: £121.5m; 30 September 2024: £104.5m). Over 80% of the order book is for delivery in FY26, which underpins increased trading in the new financial year including the full year impact of recent acquisitions, partially offset by an increase in overheads.

 

We are seeing strong demand in the Aerospace & Defence business across the UK, USA and Europe. Whilst short-term demand outlook in our Industrial and Life Sciences markets remains subdued with the exact timing of recovery unpredictable due to supply chain uncertainty and tariff challenges, we still expect the semiconductor market to start to grow modestly during the medium-term, where photonics is a key enabler of cutting-edge technologies.

Notice of Full Year Results

The Group expects to announce its full year results for the year ended 30 September 2025 on 2 December 2025.

Charlie Peppiatt, Chief Executive Officer of G&H, commented:

"I am delighted with the positive progress the Group has made in FY25. Our operational performance has shown sustained improvement and resilience in the face of a complex and uncertain macroeconomic background, with unprecedented supply chain and tariff challenges. This is a testament to the positive progress the Group is making with the deployment of our strategy and the quality of our workforce.

"The integration of both Phoenix and Global Photonics into G&H is proceeding to plan. Both businesses are an excellent strategic and operational fit for the Group. In particular, Global Photonics, acquired in May 2025, brings strong relationships with U.S. defence primes and complementary manufacturing capabilities to our growing Optical Systems division in North America. Both acquisitions are accelerators to G&H becoming a partner of choice for high-precision optical systems and photonics in the UK, US and Europe.

"With our growing order book, strengthening market positions and differentiated photonics expertise aligned to structural growth drivers from megatrends, we are increasingly confident in the prospects of the company to deliver our strategy in the medium term."

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer 

Gooch & Housego plc

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Burson Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the UK, USA and Europe. The company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is based upon unaudited management accounts and excludes any exceptional items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

3. Adjusted profit before tax excludes the amortisation of acquired intangible assets, impairment of goodwill and acquired intangible assets, non-underlying items being site closure costs, costs of acquisitions, and restructuring costs, together with the related tax impact.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSUFUMEISEFS
Date   Source Headline
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase
20th Feb 20191:07 pmRNSResult of AGM
20th Feb 20197:00 amRNSAGM Trading Update
9th Jan 201910:17 amRNSGrant of LTIP Awards
9th Jan 20197:00 amRNSSite Visit to ITL Life Science Business
28th Dec 201811:14 amRNSBlock Listing Six Monthly Return
28th Dec 201811:13 amRNSIssue of Equity and Total Voting Rights
28th Dec 201811:12 amRNSBlock Listing Application
11th Dec 20184:44 pmRNSAdditional Listing
11th Dec 20187:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 201811:30 amRNSDirector/PDMR Shareholding
5th Dec 201811:28 amRNSDirector/PDMR Shareholding
27th Nov 201811:36 amRNSDirector/PDMR Shareholding
27th Nov 20187:00 amRNSCFO Succession
27th Nov 20187:00 amRNSPreliminary Results
30th Oct 201811:06 amRNSHolding(s) in Company
29th Oct 201811:08 amRNSHolding(s) in Company
25th Oct 20184:40 pmRNSHolding(s) in Company
25th Oct 20187:00 amRNSNotification of Preliminary Results
23rd Oct 201810:23 amRNSHolding(s) in Company
4th Oct 20187:00 amRNSFull Year Trading Update
26th Sep 20189:00 amRNSHolding(s) in Company
6th Sep 20187:00 amRNSAerospace and Defence Acquisition
8th Aug 20187:00 amRNSLife Sciences Acquisition
12th Jul 20189:26 amRNSHolding(s) in Company
13th Jun 201810:08 amRNSHolding(s) in Company
6th Jun 20182:02 pmRNSDirector/PDMR Shareholding
5th Jun 20187:00 amRNSInterim Results
3rd May 20187:00 amRNSNotification of Half Year Results
6th Apr 20187:00 amRNSHalf Year Trading Update
3rd Apr 20184:35 pmRNSPrice Monitoring Extension
20th Mar 20188:25 amRNSHolding(s) in Company
21st Feb 20185:20 pmRNSResult of AGM
21st Feb 20187:00 amRNSAGM Trading Update
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
18th Jan 20181:35 pmRNSGrant of LTIP Awards
22nd Dec 20179:13 amRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.